Skip to content
2000
Volume 22, Issue 7
  • ISSN: 1567-2018
  • E-ISSN: 1875-5704
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Background

Alopecia is globally known as a distressing medical disorder that affects men and women, and current commercially available minoxidil solutions are formulated with irritant vehicles with frequent complaints of dermatologic adverse effects.

Objectives

This study aimed to investigate further the compatibility of ready-to-use vehicles for the preparation of tailored formulations for alopecia treatment, namely TrichoSol™ (a ready-to-use vehicle for personalized hair solutions) and TrichoFoam™ (a ready-to-use vehicle for personalized foam formulations), in combination with minoxidil and other active pharmaceutical ingredients (APIs), to establish adequate beyond-use dates (BUD) for the given formulations.

Methods

Products under evaluation were compounded using TrichoSol™ or TrichoFoam™, with direct incorporation of the APIs into these vehicles. Samples were then stored at controlled room temperature for up to 180 days. High-performance liquid chromatography (HPLC) methods were developed and validated, and then utilized to evaluate the compatibility of the APIs in TrichoSol™ and TrichoFoam™. Forced degradation studies were conducted to assess API stability under various stress conditions, and Antimicrobial Effectiveness Testing (AET) was performed at 0 and 180 days after compounding.

Results

According to our results, BUDs of up to 90-180 days were obtained for the examined formulations stored at room temperature, considering a degradation of maximum 10% of the nominal concentration of the APIs within them. The formulations exhibited no discernible physical alterations throughout this period and maintained chemical stability within acceptable limits. Microbiological evaluations confirmed the efficacy of the preservative system.

Conclusion

Products compounded with TrichoSol™ and TrichoFoam™ showed suitable stability to be used as personalized treatments for alopecia. We can then suggest that the vehicles TrichoSol™ and TrichoFoam™ present effective solutions for compounding personalized hair care treatments.

© 2025 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cdd/10.2174/0115672018327249241217163930
2025-01-22
2025-09-17

  • From This Site

    /content/journals/cdd/10.2174/0115672018327249241217163930
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cdd/22/7/CDD-22-7-09.html?itemId=/content/journals/cdd/10.2174/0115672018327249241217163930&mimeType=html&fmt=ahah

References

  1. JamersonT.A. AguhC. An approach to patients with alopecia.Med. Clin. North Am.2021105459961010.1016/j.mcna.2021.04.002 34059240
     [Google Scholar]
  2. HuntN. McHaleS. The psychological impact of alopecia.BMJ2005331752295195310.1136/bmj.331.7522.951 16239692
     [Google Scholar]
  3. YuL. MoorthyS. PengL. ShenL. HanY. ZhangZ. LiY. HuangX. Evaluation of anxiety and depression in patients with androgenetic alopecia in Shanghai: A cross‐sectional study.Dermatol. Ther.202320231514062010.1155/2023/5140620
     [Google Scholar]
  4. YuN. GuoY. Association between alopecia areata, anxiety, and depression: Insights from a bidirectional two-sample Mendelian randomization study.J. Affect. Disord.202435032833110.1016/j.jad.2024.01.152 38242214
     [Google Scholar]
  5. GordonK. GordonK. TostiA. Alopecia: Evaluation and treatment.Clin. Cosmet. Investig. Dermatol.2011410110610.2147/CCID.S10182 21833160
     [Google Scholar]
  6. LolliF. PallottiF. RossiA. FortunaM.C. CaroG. LenziA. SansoneA. LombardoF. Androgenetic alopecia: A review.Endocrine201757191710.1007/s12020‑017‑1280‑y 28349362
     [Google Scholar]
  7. MirmiraniP. KhumaloN.P. Traction alopecia.Dermatol. Clin.201432215316110.1016/j.det.2013.12.003 24680002
     [Google Scholar]
  8. PrattC.H. KingL.E.Jr MessengerA.G. ChristianoA.M. SundbergJ.P. Alopecia areata.Nat. Rev. Dis. Primers2017311701110.1038/nrdp.2017.11 28300084
     [Google Scholar]
  9. RahangdaleP.C. WankhadeA.M. A review on-types and treatment of alopecia.Asian J. Pharm. Res.202313212312810.52711/2231‑5691.2023.00025
     [Google Scholar]
  10. KoniskyH. BalazicE. KobetsK. Characterization of alopecia clinical trials: An analysis of trials registered on clinicaltrials.gov.Arch. Dermatol. Res.2024316411610.1007/s00403‑024‑02850‑3 38558185
     [Google Scholar]
  11. NestorM.S. AblonG. GadeA. HanH. FischerD.L. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.J. Cosmet. Dermatol.202120123759378110.1111/jocd.14537 34741573
     [Google Scholar]
  12. GorenA. NaccaratoT. Minoxidil in the treatment of androgenetic alopecia.Dermatol. Ther.2018315e1268610.1111/dth.12686 30155952
     [Google Scholar]
  13. RambwawasvikaH. Alopecia types, current and future treatment.J. Cosmet. Dermatol.202154939910.15406/jdc.2021.05.00190
     [Google Scholar]
  14. ShenY. ZhuY. ZhangL. SunJ. XieB. ZhangH. SongX. New target for Minoxidil in the treatment of androgenetic alopecia.Drug Des. Devel. Ther.2023172537254710.2147/DDDT.S427612 37645625
     [Google Scholar]
  15. RavalR.S. NohriaA. DesaiD. MourtzanakisK. BuontempoM. ShapiroJ. Lo SiccoK. The use of minoxidil in the treatment of alopecia areata: A systematic review.J. Am. Acad. Dermatol.202491350850910.1016/j.jaad.2024.05.037 38796079
     [Google Scholar]
  16. StoehrJ.R. ChoiJ.N. ColavincenzoM. VanderweilS. Off-label use of topical minoxidil in alopecia: A review.Am. J. Clin. Dermatol.201920223725010.1007/s40257‑018‑0409‑y 30604379
     [Google Scholar]
  17. SuchonwanitP. ThammaruchaS. LeerunyakulK. Minoxidil and its use in hair disorders: A review.Drug Des. Devel. Ther.2019132777278610.2147/DDDT.S214907 31496654
     [Google Scholar]
  18. FriedmanE.S. FriedmanP.M. CohenD.E. WashenikK. Allergic contact dermatitis to topical minoxidil solution: Etiology and treatment.J. Am. Acad. Dermatol.200246230931210.1067/mjd.2002.119104 11807448
     [Google Scholar]
  19. SuneelR.S. ShivaniV. Nikhil KumarA. AmeyK. SuyogM. SujeetM. CharugullaN. Comparative study to evaluate tolerability of topical 5% Minoxidil novel formulation and alcohol-based conventional solutions in treatment of androgenetic alopecia in Indian men: Randomized double-blind Study.Dermatol. Ther. (Heidelb.)20201046947910.6084/m9.figshare.12029772
     [Google Scholar]
  20. AmaralF. JardimM. de Souza AntunesV.M. MichelinL.F.G. dos SantosB.A.R. BarbosaC.M.V. SpindolaD.G. BincolettoC. OliveiraC.R. EEffects of the phytocomplex TrichoTechTM on human fibroblasts: Proliferative potential and effects on gene expression of FGF-7 and FGF-10.J. Cosmet. Dermatol. Sci. Applic.20170711310.4236/jcdsa.2017.71001
     [Google Scholar]
  21. PoloniniH.C. TaylorS. SilvaC.C.V. Compatibility of cetirizine hydrochloride, dutasteride, hydrocortisone acetate, nicotinamide, progesterone, and pyridoxine hydrochloride in TrichoSolTM, A natural vehicle for hair solutions.Int. J. Pharm. Compd.202428440447 39405573
     [Google Scholar]
  22. PoloniniH.C. SousaP.L. SilvaC.C.V. Compatibility of caffeine clobetasol propionate dutasteride nicotinamide and progesterone in TrichoFoam™, a natural vehicle for hair foams.Int. J. Pharm. Compd.2024282161168 38604144
     [Google Scholar]
  23. PoloniniH. TaylorS. ZanderC. Compatibility of different formulations in TrichoConceptTM vehicles for hair treatments.Sci. Pharm.20229011610.3390/scipharm90010016
     [Google Scholar]
  24. PoloniniH.C. SilvaC.C.V. Compounded hair solutions and foams containing Minoxidil: Does the color change impact stability?Sci. Pharm.20239133910.3390/scipharm91030039
     [Google Scholar]
  25. PanchaprateepR. Medical treatment for androgenetic alopecia.Facial Plast. Surg.202440225226610.1055/a‑2196‑4713 37871637
     [Google Scholar]
  26. KimJ.H. LeeS.Y. LeeH.J. YoonN.Y. LeeW.S. The efficacy and safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) solution on female pattern hair loss: Single center, open-label, non-comparative, phase iv study.Ann. Dermatol.201224329530510.5021/ad.2012.24.3.295 22879713
     [Google Scholar]
  27. MolinelliE. CampanatiA. BrisigottiV. SapigniC. PaolinelliM. OffidaniA. Efficacy and safety of topical calcipotriol 0.005% versus topical clobetasol 0.05% in the management of alopecia areata: An intrasubject pilot study.Dermatol. Ther. (Heidelb.)202010351552110.1007/s13555‑020‑00379‑7 32342443
     [Google Scholar]
  28. PiracciniB.M. Blume-PeytaviU. ScarciF. JansatJ.M. FalquésM. OteroR. TamaritM.L. GalvánJ. TebbsV. MassanaE. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: A phase III, randomized, controlled clinical trial.J. Eur. Acad. Dermatol. Venereol.202236228629410.1111/jdv.17738 34634163
     [Google Scholar]
  29. Pindado-OrtegaC. Saceda-CorraloD. Moreno-ArronesÓ.M. Rodrigues-BarataA.R. Hermosa-GelbardÁ. Jaén-OlasoloP. Vañó-GalvánS. Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice.J. Am. Acad. Dermatol.20218451285129410.1016/j.jaad.2020.09.093 33038469
     [Google Scholar]
  30. DingY. WangC. BiL. DuY. LuC. ZhaoM. FanW. Dutasteride for the treatment of androgenetic alopecia: An updated review.Dermatology20242405-683384310.1159/000541395 39278205
     [Google Scholar]
  31. KoralewiczM.M. SzatkowskaO.A. Topical solutions for androgenetic alopecia: Evaluating efficacy and safety.Forum Dermatologicum2024103717810.5603/fd.101208
     [Google Scholar]
  32. FieldsJ.R. VonuP.M. MonirR.L. SchochJ.J. Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review.Dermatol. Ther.2020331e1320210.1111/dth.13202 31858672
     [Google Scholar]
  33. U.S. Pharmacopeial Convention. Pharmaceutical compounding - Nonsterile preparations. In United States Pharmacopeia.2024Available from: https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/gc-795-rb-notice-20200424.pdf
  34. DrugsCom Available from: https://www.drugs.com/ (accessed on 13 July 2023).
  35. SweetmanS.C. Martindale: The complete drug reference.J. Med. Libr. Assoc.2012100757610.3163/1536‑5050.100.1.018
     [Google Scholar]
  36. ICH Q1A (R2) stability testing of new drug substances and drug products: Scientific guideline.2024Available from: https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf
  37. PoloniniH. MarianniB. TaylorS. ZanderC. Compatibility of personalized formulations in Cleoderm™, A skin rebalancing cream base for oily and sensitive skin.Cosmetics2022959210.3390/cosmetics9050092
     [Google Scholar]
  38. GuyR.C. International conference on harmonisationEncyclopedia of ToxicologyAcademic Press201410701070
     [Google Scholar]
  39. Validation of analytical procedures: Text and methodology Q2(R1)2005Available from: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf
  40. Validation of microbial recovery from pharmacopeial articles. United States PharmacopeiaAvailable from: https://doi.usp.org/USPNF/USPNF_M99947_03_01.html
  41. Antimicrobial effectiveness testing. In USPNF.2024Available from: https://doi.usp.org/USPNF/USPNF_M98790_03_01.html
  42. European Medicines AgencyICH Q1D Bracketing and matrixing designs for stability testing of drug substances and drug products: Scientific guideline.https://www.ema.europa.eu/en/ich-q1d-bracketing-matrixing-designs-stability-testing-drug-substances-drug-products-scientific
  43. GeigerC.M. SorensonB. WhaleyP.A. Stability of minoxidil in Espumil foam base.Int. J. Pharm. Compd.2013172165167 23696178
     [Google Scholar]
  44. LupatiniR. SidhuR. PatelH. BicharK. Stability evaluation of minoxidil in FOAMIL foam base with bracketing study design.Int. J. Pharm. Compd.2021253236240https://pubmed.ncbi.nlm.nih.gov/34125714/ 34125714
     [Google Scholar]
  45. SpennacchioA. LopedotaA.A. LopalcoA. DibenedettoM.T. la ForgiaF.M. FontanaS. FrancoM. DenoraN. Extemporaneous topical Minoxidil solutions for the treatment of alopecia: Stability studies and incorporation tests of active ingredients in ALOPLUS FAST base.Int. J. Pharm. Compd.2023273256262https://pubmed.ncbi.nlm.nih.gov/37267529/ 37267529
     [Google Scholar]
  46. PappasL. KissA. LevittJ. Compatibility of tacrolimus ointment with corticosteroid ointments of varying potencies.J. Cutan. Med. Surg.200913314014510.2310/7750.2008.08013 19426622
     [Google Scholar]
  47. AliM.S. AlamM.S. AlamN. AnwerT. SafhiM.M. Accelerated stability testing of a clobetasol propionate loaded nanoemulsion as per ICH guideline.Sci. Pharm.20138141089110010.3797/scipharm.1210‑02 24482775
     [Google Scholar]
  48. KumarR. SinghB. BakshiG. KatareO.P. Development of liposomal systems of finasteride for topical applications: Design, characterization, and in vitro evaluation.Pharm. Dev. Technol.200712659160110.1080/10837450701481181 18161632
     [Google Scholar]
  49. AfiuneL.A.F. UshirobiraC.Y. BarbosaD.P.P. de SouzaP.E.N. LelesM.I.G. Cunha-FilhoM. GelfusoG.M. SolerM.A.G. GratieriT. Novel iron oxide nanocarriers loading finasteride or dutasteride: Enhanced skin penetration for topical treatment of alopecia.Int. J. Pharm.202058711970910.1016/j.ijpharm.2020.119709 32739394
     [Google Scholar]
  50. AliM.S. AlamM.S. AlamN. SiddiquiM.R. Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy.Iran. J. Pharm. Res.201413411251140 25587300
     [Google Scholar]
  51. SkibaM. Skiba-LahianiM. MarchaisH. DuclosR. ArnaudP. Stability assessment of ketoconazole in aqueous formulations.Int. J. Pharm.200019811610.1016/S0378‑5173(99)00279‑3 10722946
     [Google Scholar]
/content/journals/cdd/10.2174/0115672018327249241217163930
Loading
Exploring the Physicochemical Compatibility of Minoxidil in Combination with Different Active Pharmaceutical Ingredients in Ready-to-use Vehicles for Alopecia Treatment
Curr. Drug Deliv. 22, 983 (2025); https://doi.org/10.2174/0115672018327249241217163930
/content/journals/cdd/10.2174/0115672018327249241217163930
/content/journals/cdd/10.2174/0115672018327249241217163930
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Alopecia; beyond-use date; chemical analysis; compatibility study; dermatology; medical treatment; personalized medicine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test